Literature DB >> 16753868

Cardiopulmonary exercise testing in the evaluation of functional capacity after treatment of lymphomas in adults.

Lubomir Elbl1, Ingrid Vasova, Iva Tomaskova, Frantisek Jedlicka, Zdenek Kral, Milan Navratil, Lenka Smardova, Barbora Wagnerova, Jiri Vorlicek.   

Abstract

The present study assessed several parameters of cardiopulmonary function in patients, after treatment for aggressive non-Hodgkin's lymphoma and Hodgkin's disease, to determine the influence of these parameters on patient's performance status. One hundred and six patients (66 male and 40 female) aged 40 +/- 15 years were examined 1-2 years (median 14 months) after anticancer treatment. The patients were examined by means of rest and dynamic stress echocardiography and cardiopulmonary exercise. The rest and post-exercise ejection fraction (EF), Doppler parameters of left ventricular diastolic function and peak oxygen consumption (pVO2) were used as parameters of cardiopulmonary performance. The cumulative dose (CD) of doxorubicin (DOX) given was 240 +/- 70 (240 mg/m2). Thirty-seven percent of patients received mediastinal irradiation in accordance with the used treatment protocol. Sixty-four patients (60%) experienced fatigue after the treatment. Three patients (3%) demonstrated an decreased EF <50%, 34 (32%) demonstrated impaired diastolic function, 14 (13%) demonstrated decreased pVO2<20 ml/kg/min and 15 (14%) demonstrated a value of pVO2 below the reference value, respectively. None of the patients exhibited clinical signs of heart failure. Apart from three patients with a rest EF<50%, all the other patients responded to stress echocardiography with an increment of EF > 5%. The parameter pVO2 significantly correlated with stress EF (0.58, P < 0.0002). A significant relationship was found with all parameters of diastolic function: to index E/A of diastolic filling (r = 0.67, P < 0.0001), isovolumic relaxation time (r = -0.56, P < 0.0009) and to deceleration time (r = -0.54, P < 0.009), respectively. A negative relationship was found with age (r = -0.74, P < 0.0001), CD of DOX (r = -0.53, P < 0.003) and radiotherapy-involving mediastinum (r = - 0.44, P < 0.04), respectively. Using multivariate analysis, a significant relationship was found between pVO2 and parameters of diastolic filling, age, female sex and CD of DOX, respectively (r = 0.58, P < 0.0001). Diastolic dysfunction was correlated with age, CD of DOX and radiotherapy-involving mediastinum, respectively (r = 0.51, P < 0.01). The results show that diastolic dysfunction was the most affected parameter of cardiopulmonary function in cancer survivors. This parameter negatively influenced cardiopulmonary performance and was significantly correlated with the cumulative dose of doxorubicin given and radiotherapy on mediastinum. Despite a high number of patients experiencing fatigue, the study demonstrates that only a relatively small number of patients show a depressed pVO2 on a cardiopulmonary stress test and other cardiac abnormalities. The results of the tests support the introduction of regular aerobic exercise for cancer survivors to increase their cardiopulmonary performance and well-being. Hypothetically, aerobic training may also positively influence diastolic function. However, this assumption warrants a prospective follow-up.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16753868     DOI: 10.1080/10428190500402559

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  12 in total

1.  TNF/TNFR1 signaling mediates doxorubicin-induced diaphragm weakness.

Authors:  Laura A A Gilliam; Jennifer S Moylan; Leonardo F Ferreira; Michael B Reid
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-11-19       Impact factor: 5.464

2.  Exercise stimulates beneficial adaptations to diminish doxorubicin-induced cellular toxicity.

Authors:  Ashley J Smuder
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2019-08-28       Impact factor: 3.619

3.  Comparison of physiological response to cardiopulmonary exercise testing among cancer survivors and healthy controls.

Authors:  Riggs J Klika; Katharina S Golik; Scott N Drum; Kathleen E Callahan; William G Thorland
Journal:  Eur J Appl Physiol       Date:  2010-12-03       Impact factor: 3.078

4.  Doxorubicin causes diaphragm weakness in murine models of cancer chemotherapy.

Authors:  Laura A A Gilliam; Jennifer S Moylan; Leigh Ann Callahan; Marius P Sumandea; Michael B Reid
Journal:  Muscle Nerve       Date:  2011-01       Impact factor: 3.217

Review 5.  Chemotherapy-induced weakness and fatigue in skeletal muscle: the role of oxidative stress.

Authors:  Laura A A Gilliam; Daret K St Clair
Journal:  Antioxid Redox Signal       Date:  2011-06-15       Impact factor: 8.401

6.  Doxorubicin acts through tumor necrosis factor receptor subtype 1 to cause dysfunction of murine skeletal muscle.

Authors:  Laura A A Gilliam; Leonardo F Ferreira; Joseph D Bruton; Jennifer S Moylan; Håkan Westerblad; Daret K St Clair; Michael B Reid
Journal:  J Appl Physiol (1985)       Date:  2009-09-24

7.  Pilot Feasibility Study of Comprehensive Pulmonary Evaluation Following Lung Radiation Therapy.

Authors:  Aliva De; Leo Mascarenhas; Sunil Kamath; Alejandro LaRiviere; Fariba Goodarzian; Thomas G Keens; Rajkumar Venkatramani
Journal:  J Pediatr Hematol Oncol       Date:  2015-10       Impact factor: 1.289

8.  Mitochondrial accumulation of doxorubicin in cardiac and diaphragm muscle following exercise preconditioning.

Authors:  Aaron B Morton; Andres Mor Huertas; J Matthew Hinkley; Noriko Ichinoseki-Sekine; Demetra D Christou; Ashley J Smuder
Journal:  Mitochondrion       Date:  2018-02-21       Impact factor: 4.160

9.  Modification of Neuromuscular Junction Protein Expression by Exercise and Doxorubicin.

Authors:  Andres Mor Huertas; Aaron B Morton; J Matthew Hinkey; Noriko Ichinoseki-Sekine; Ashley J Smuder
Journal:  Med Sci Sports Exerc       Date:  2020-07

10.  Personalized home-based interval exercise training may improve cardiorespiratory fitness in cancer patients preparing to undergo hematopoietic cell transplantation.

Authors:  W A Wood; B Phillips; A E Smith-Ryan; D Wilson; A M Deal; C Bailey; M Meeneghan; B B Reeve; E M Basch; A V Bennett; T C Shea; C L Battaglini
Journal:  Bone Marrow Transplant       Date:  2016-03-21       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.